These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 14634401)

  • 1. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
    Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
    Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
    Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
    Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
    Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
    Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
    Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
    Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
    Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
    J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
    Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
    Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
    Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
    J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
    Fiore CE; Pennisi P; Ferro G; Ximenes B; Privitelli L; Mangiafico RA; Santoro F; Parisi N; Lombardo T
    Horm Metab Res; 2006 Jun; 38(6):417-22. PubMed ID: 16823725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
    Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
    Burton DW; Geller J; Yang M; Jiang P; Barken I; Hastings RH; Hoffman RM; Deftos LJ
    Prostate; 2005 Feb; 62(3):275-81. PubMed ID: 15389781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
    Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
    Brown JM; Vessella RL; Kostenuik PJ; Dunstan CR; Lange PH; Corey E
    Clin Cancer Res; 2001 Oct; 7(10):2977-83. PubMed ID: 11595685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
    Rogers A; Eastell R
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.